Verona Pharma plc (VRNA)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Total revenue, net | 103,138 | 5,624 | ||
| Research and development | - | 10,552 | ||
| Research and development | 12,950 | - | ||
| Cost of sales | 4,756 | 543 | ||
| Selling, general and administrative | 72,127 | 35,196 | ||
| Total operating expenses | 89,833 | 46,291 | ||
| Operating income/(loss) | 13,305 | -40,667 | ||
| Foreign exchange gain(loss) | - | 1,475 | ||
| Interest expense | - | 9,882 | ||
| Research and development tax credit | - | 1,612 | ||
| Interest income | 4,302 | 4,750 | ||
| Interest expense | 6,822 | - | ||
| Loss on extinguishment of debt | - | - | ||
| Foreign exchange gain/(loss) | 1,097 | - | ||
| Total other (expense)/income, net | -1,423 | -2,045 | ||
| Income/(loss) before income taxes | 11,882 | -42,712 | ||
| Income tax benefit/(expense) | -39 | 250 | ||
| Net income/(loss) | 11,921 | -42,962 | ||
| Profit/(loss) per share, basic (in dollars per share) | 0.02 | -0.07 | ||
| Profit/(loss) per share, diluted (in dollars per share) | 0.02 | -0.07 | ||
| Weighted-average shares outstanding, basic (in shares) | 685,155,000 | 651,944,000 | ||
| Weighted-average shares outstanding, diluted (in shares) | 727,223,000 | 651,944,000 | ||